Experience of phamacokinetically guided topotecan administration for chemotherapy resistant Wilms tumor

• Aoki,Yuki

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Takagi,Masatoshi

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Maeda,Yoshitika

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Arai,Hiromi

  Department of Hospital Pharmacy, Tokyo Medical and Dental University

• Takahashi,Mayumi

  Department of Hospital Pharmacy, Tokyo Medical and Dental University

• Shibata,Satoko

  Department of Hospital Pharmacy, Tokyo Medical and Dental University

• Isoda,Takeshi

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Mitsuiki,Noriko

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Nagasawa,Masayuki

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Morio,Tomohiro

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

• Yasuhara,Masato

  Department of Hospital Pharmacy, Tokyo Medical and Dental University

• Mizutani,Shuki

  Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School

Bibliographic Information

Other Title

• 化学療法抵抗性を示したWilms腫瘍に対する薬物動態解析にもとづくトポテカン(ノギテカン)の投与経験

Abstract

Topotecan was administrated for a refractory Wilms tumor Stage IV patient under the phamacokineticaly guided dose monitoring approach. Topotecan 1.5mg/m^2/dose was administrated for 5 consecutive days. Then, AUC was calculated on the first day of administration. After a two day interval, a 3.1mg/m^2/dose of Topotecan was administrated for 4 consecutive days based on predicted AUC that could achieve AUC 92±10ng/ml×hr. Unfortunately, the disease progressed in spite of Topotecan therapy. The efficiency of Topotecan was not elucidated in this study.

Journal

• 小児がん : 小児悪性腫瘍研究会記録

  小児がん : 小児悪性腫瘍研究会記録 46 (3), 337-342, 2009-09-25

  がんの子供を守る会

Keywords

• topotecan
• pharmacokinetics
• Wilms tumor

Details

• CRID: 1541417145288059776
• NII Article ID: 110007359137
• NII Book ID: AN00116159
• Web Site: http://dl.ndl.go.jp/info:ndljp/pid/10755245
• Web Site: https://search.jamas.or.jp/link/ui/2009340556
• Text Lang: ja
• Data Source:
  • NDL-Digital
  • CiNii Articles
  • KAKEN